BMC CANCER

Scope & Guideline

Empowering Discoveries in Oncology

Introduction

Welcome to your portal for understanding BMC CANCER, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN-
PublisherBMC
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationBMC CANCER / BMC Cancer
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

BMC CANCER is dedicated to publishing high-quality research articles covering the broad spectrum of cancer research. The journal focuses on studies that advance our understanding of cancer biology, treatment, and prevention, with a strong emphasis on translational research and clinical implications.
  1. Cancer Biology and Mechanisms:
    Research exploring the molecular and cellular mechanisms underlying cancer development and progression, including studies on genetic mutations, epigenetic changes, and tumor microenvironment interactions.
  2. Clinical Oncology and Treatment Strategies:
    Investigations into various treatment modalities for cancer patients, including chemotherapy, radiotherapy, immunotherapy, and novel therapeutic agents, along with studies assessing treatment efficacy and safety.
  3. Epidemiology and Public Health:
    Studies addressing cancer epidemiology, including risk factors, incidence, prevalence, and survival rates, particularly in diverse populations and underrepresented communities.
  4. Biomarkers and Early Detection:
    Research focused on identifying novel biomarkers for cancer diagnosis, prognosis, and treatment response, as well as studies on screening methods and technologies for early cancer detection.
  5. Patient-Centered Outcomes:
    Investigations into health-related quality of life, patient experiences, and psychosocial aspects of cancer care, highlighting the importance of patient perspectives in oncology.
  6. Translational Research:
    Studies bridging laboratory findings with clinical applications, aiming to translate basic research discoveries into effective cancer therapies and improved patient outcomes.
BMC CANCER is witnessing several emerging themes that reflect the evolving landscape of cancer research. These trends indicate a shift towards more integrative and patient-focused approaches in oncology.
  1. Immunotherapy and Immune Profiling:
    Research on immunotherapy, including immune checkpoint inhibitors and CAR-T cell therapies, is rapidly increasing, focusing on understanding immune responses and patient stratification based on immune profiles.
  2. Microbiome and Cancer Relationships:
    An emerging area of interest is the relationship between the microbiome and cancer, with studies exploring how gut microbiota influences cancer development, treatment responses, and patient outcomes.
  3. Precision Medicine and Genomic Profiling:
    There is a growing emphasis on precision medicine, with researchers focusing on genomic profiling to tailor treatments based on individual patient characteristics and tumor genetics.
  4. Patient-Reported Outcomes and Quality of Life:
    Increasing attention is being paid to patient-reported outcomes and quality of life assessments, emphasizing the importance of holistic care and survivorship issues in cancer management.
  5. Artificial Intelligence and Machine Learning in Oncology:
    The integration of AI and machine learning techniques in cancer research is gaining traction, with applications in early detection, treatment prediction, and personalized therapy planning.
  6. Long Non-Coding RNAs in Cancer:
    Research into long non-coding RNAs as potential biomarkers and therapeutic targets is on the rise, reflecting a broader interest in the regulatory roles of non-coding RNA in cancer biology.

Declining or Waning

While BMC CANCER continues to thrive in various areas, certain themes have shown a decline in recent publications, indicating a shift in focus within the cancer research community.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decrease in studies solely focused on traditional chemotherapy regimens, as the field shifts towards exploring combination therapies and personalized treatment approaches.
  2. Basic Science without Clinical Relevance:
    Research articles that focus exclusively on basic science findings without clear clinical implications are becoming less prevalent, as the emphasis now leans towards translational research with direct applications in patient care.
  3. Single-Institution Studies:
    The trend is moving away from single-institution studies towards multi-center collaborations and larger cohort analyses, which provide more generalizable results and insights.
  4. Longitudinal Studies without Novel Insights:
    Longitudinal studies that do not introduce new methodologies or significant findings related to cancer treatment or patient outcomes are less frequently published, reflecting a preference for innovative research.

Similar Journals

BULLETIN DU CANCER

Pioneering discoveries in cancer treatment and diagnostics.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0007-4551Frequency: 12 issues/year

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

Oncology Letters

Exploring New Frontiers in Cancer Treatment and Care
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Nature Cancer

Inspiring Collaboration for Cancer Advances
Publisher: NATURE PORTFOLIOISSN: Frequency: 12 issues/year

Nature Cancer, published by NATURE PORTFOLIO, stands at the forefront of oncological research with a robust impact within the scientific community. As an esteemed journal with impressive rankings—#12 in Medicine (Oncology) and #8 in Biochemistry, Genetics and Molecular Biology (Cancer Research) according to Scopus, placing it within the 97th and 96th percentiles respectively—Nature Cancer boasts a Q1 category status in both Cancer Research and Oncology for 2023. The journal's commitment to advancing cancer research is crucial, promoting high-quality, peer-reviewed studies that address the complexities of cancer biology and treatment. By facilitating open access to impactful findings, Nature Cancer aims to foster collaboration and inspire innovative approaches among researchers, professionals, and students alike, making significant strides in the global fight against cancer. As this pivotal publication continues its converged years from 2020 to 2024, it heralds a future ripe with transformative insights and breakthroughs in the vital field of oncology.

CANCER SCIENCE

Leading the charge in innovative cancer treatment solutions.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

Cancer Reports

Championing innovation in oncology research.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

BRITISH JOURNAL OF CANCER

Pioneering Insights in Oncology Since 1947.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Breast Cancer

Transforming insights into impactful breast cancer solutions.
Publisher: SPRINGER JAPAN KKISSN: 1340-6868Frequency: 6 issues/year

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

Cancer Research Communications

Bridging gaps in cancer knowledge and practice.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Championing Excellence in Cancer Research and Clinical Practice.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Oncology Research and Treatment

Fostering dialogue for a brighter future in oncology.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.